PMC:7195088 / 45031-45496 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1329","span":{"begin":43,"end":48},"obj":"Species"},{"id":"1330","span":{"begin":87,"end":100},"obj":"Species"},{"id":"1331","span":{"begin":102,"end":112},"obj":"Species"},{"id":"1332","span":{"begin":114,"end":122},"obj":"Species"},{"id":"1333","span":{"begin":129,"end":137},"obj":"Species"},{"id":"1334","span":{"begin":274,"end":282},"obj":"Species"},{"id":"1336","span":{"begin":412,"end":422},"obj":"Chemical"},{"id":"1337","span":{"begin":265,"end":273},"obj":"Disease"}],"attributes":[{"id":"A1329","pred":"tao:has_database_id","subj":"1329","obj":"Tax:1570291"},{"id":"A1330","pred":"tao:has_database_id","subj":"1330","obj":"Tax:11118"},{"id":"A1331","pred":"tao:has_database_id","subj":"1331","obj":"Tax:2697049"},{"id":"A1332","pred":"tao:has_database_id","subj":"1332","obj":"Tax:694009"},{"id":"A1333","pred":"tao:has_database_id","subj":"1333","obj":"Tax:1335626"},{"id":"A1334","pred":"tao:has_database_id","subj":"1334","obj":"Tax:9606"},{"id":"A1336","pred":"tao:has_database_id","subj":"1336","obj":"MESH:C000606551"},{"id":"A1337","pred":"tao:has_database_id","subj":"1337","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"alogue undergoing clinical development for Ebola and showing in vitro activity against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV) and favourable effects in animal MERS models [[23], [24], [25], [26]]. Following these promising preclinical findings, RCT in COVID-19 patients have been initiated (Table 2). However, pending their results, and considering the investigational nature of the drug, access to remdesivir outside RCT is currently provided only wit"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T246","span":{"begin":43,"end":48},"obj":"Disease"},{"id":"T247","span":{"begin":102,"end":110},"obj":"Disease"},{"id":"T248","span":{"begin":114,"end":122},"obj":"Disease"},{"id":"T249","span":{"begin":265,"end":273},"obj":"Disease"}],"attributes":[{"id":"A246","pred":"mondo_id","subj":"T246","obj":"http://purl.obolibrary.org/obo/MONDO_0005737"},{"id":"A247","pred":"mondo_id","subj":"T247","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A248","pred":"mondo_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A249","pred":"mondo_id","subj":"T249","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"alogue undergoing clinical development for Ebola and showing in vitro activity against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV) and favourable effects in animal MERS models [[23], [24], [25], [26]]. Following these promising preclinical findings, RCT in COVID-19 patients have been initiated (Table 2). However, pending their results, and considering the investigational nature of the drug, access to remdesivir outside RCT is currently provided only wit"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T263","span":{"begin":70,"end":78},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T264","span":{"begin":165,"end":171},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_33208"}],"text":"alogue undergoing clinical development for Ebola and showing in vitro activity against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV) and favourable effects in animal MERS models [[23], [24], [25], [26]]. Following these promising preclinical findings, RCT in COVID-19 patients have been initiated (Table 2). However, pending their results, and considering the investigational nature of the drug, access to remdesivir outside RCT is currently provided only wit"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T551","span":{"begin":396,"end":400},"obj":"Chemical"},{"id":"T552","span":{"begin":412,"end":422},"obj":"Chemical"}],"attributes":[{"id":"A551","pred":"chebi_id","subj":"T551","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A552","pred":"chebi_id","subj":"T552","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"alogue undergoing clinical development for Ebola and showing in vitro activity against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV) and favourable effects in animal MERS models [[23], [24], [25], [26]]. Following these promising preclinical findings, RCT in COVID-19 patients have been initiated (Table 2). However, pending their results, and considering the investigational nature of the drug, access to remdesivir outside RCT is currently provided only wit"}

{"project":"LitCovid-sentences","denotations":[{"id":"T360","span":{"begin":210,"end":313},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"alogue undergoing clinical development for Ebola and showing in vitro activity against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV) and favourable effects in animal MERS models [[23], [24], [25], [26]]. Following these promising preclinical findings, RCT in COVID-19 patients have been initiated (Table 2). However, pending their results, and considering the investigational nature of the drug, access to remdesivir outside RCT is currently provided only wit"}

{"project":"2_test","denotations":[{"id":"32360444-32020029-22369764","span":{"begin":186,"end":188},"obj":"32020029"},{"id":"32360444-31924756-22369765","span":{"begin":192,"end":194},"obj":"31924756"},{"id":"32360444-32054787-22369766","span":{"begin":198,"end":200},"obj":"32054787"}],"text":"alogue undergoing clinical development for Ebola and showing in vitro activity against coronaviruses (SARS-CoV-2, SARS-CoV-1 and MERS-CoV) and favourable effects in animal MERS models [[23], [24], [25], [26]]. Following these promising preclinical findings, RCT in COVID-19 patients have been initiated (Table 2). However, pending their results, and considering the investigational nature of the drug, access to remdesivir outside RCT is currently provided only wit"}